Menu Back toSession-3-Patient-Relevant-Outcomes-from-Drug-Development-to-Clinical-Practice
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Real World Evidence Conference
Session 3: Patient Relevant Outcomes from Drug Development to Clinical Practice
- Director, VEO, Real World Evidence Policy and Advocacy
- GlaxoSmithKline, United Kingdom
- RWE Strategy Lead, Immunology
- UCB Pharma, Inc., Belgium
Most outcomes (endpoints) used in clinical trials are not designed for sustainable use in clinical practice and do not reflect treatment impact in a larger population over the long term. Focusing on outcomes that matter most to patients, and can be measured in both trials and clinical practice, would support better decision making for individual patients and population-level health. During this session, we will discuss current initiatives that are driving a new approach to more aligned outcome measurement and broader stakeholder input in measure development. We also will highlight use cases of objective outcome measures – including patient-reported outcomes (PROs) and clinician -reported outcomes (ClinROs) – that can be used continuously in trials and clinical practice.
Eileen Mack Thorley, MPH
- Senior Research Scientist
- PatientsLikeMe, United States
The Outcomes Landscape
Donna Messner, PhD
- President and CEO
- Center for Medical Technology Policy (CMTP), United States
Jean Rommes, PhD, MS
- Patient Advocate
- United States